ClinicalTrials.gg
CompletedNCT02448303KEYNOTE166Updated Sep 12, 2019Results posted

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of Pembrolizumab and Acalabrutinib in Carcinoma, Non-Small-Cell Lung, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
91st of 137
74 · median 152
Started
2015
with 13 others
Phase 2
38 of 209
2 open now
Registered
75th of 209
by date

Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 91st largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2015, is one of 38 in phase 2, and was the 75th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • performance status of 0 or 1
  • confirmed recurrent or NSCLC (adenocarcinoma, large cell, squamous cell, or not otherwise specified) that has either progressed during or after platinum-based chemotherapy
  • Received at least 1 platinum-based chemotherapy regimen. Note: Subjects with EGFR mutations or ALK translocations are required to have received prior therapy with appropriate TKI; prior platinum-based chemotherapy is not required for this specific patient population

Exclusion criteria

Exclusion Criteria:

  • Prior (other than lung cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years
  • Known central nervous system and/or carcinomatous meningitis
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass
  • Breastfeeding or pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Arm 1

    pembrolizumab

    Drug: Pembrolizumab

  • Experimental
    Arm 2

    acalabrutinib plus pembrolizumab

    Drug: Pembrolizumab · Drug: Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Overall Response

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Every 12 weeks for up to 2 years

07

Results

Posted Sep 12, 2019

Participant flow

Participant flow — Overall Study
MilestoneArm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
Started3836
Enrolled3836
Received study medication3335
Discontinued study3836
Completed00
Not completed3836

Outcome measures

PrimaryNumber of Participants With Overall Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Every 12 weeks for up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Overall Response
ParticipantsArm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
Number of Participants With Overall Response44

Adverse events

Collected over Safety Analysis tracked from 0 day to 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Pembrolizumab Monotherapy18/33 (54.5%)12/33 (36.4%)33/33 (100%)
Arm 2 - Acalabrutinib + Pembrolizumab23/35 (65.7%)18/35 (51.4%)35/35 (100%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventArm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
DyspnoeaRespiratory, thoracic and mediastinal disorders1/334/35
PneumoniaInfections and infestations1/333/35
DysphagiaGastrointestinal disorders2/331/35
DehydrationMetabolism and nutrition disorders2/331/35
HypoxiaRespiratory, thoracic and mediastinal disorders2/331/35
PneumonitisRespiratory, thoracic and mediastinal disorders2/330/35
AnaemiaBlood and lymphatic system disorders1/331/35
Gastrointestinal HaemorrhageGastrointestinal disorders1/330/35
Large Intestine HaemorrhageGastrointestinal disorders1/330/35
StomatitisGastrointestinal disorders1/330/35
Most frequent other events
Showing 10 of 95
Most frequent other events
EventArm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
FatigueGeneral disorders15/339/35
VomitingGastrointestinal disorders3/3313/35
NauseaGastrointestinal disorders5/3312/35
Decreased AppetiteMetabolism and nutrition disorders6/3312/35
DiarrheaGastrointestinal disorders7/3311/35
DyspnoeaRespiratory, thoracic and mediastinal disorders8/3311/35
CoughRespiratory, thoracic and mediastinal disorders6/3310/35
AnaemiaBlood and lymphatic system disorders5/339/35
ConstipationGastrointestinal disorders3/337/35
Oedema PeripheralGeneral disorders5/337/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
Mean63.7 ± 10.264.6 ± 9.3364.2 ± 9.70
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
Female152035
Male181533
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
Hispanic or Latino112
Not Hispanic or Latino323466
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
American Indian or Alaska Native000
Asian246
Native Hawaiian or Other Pacific Islander000
Black or African American448
White252752
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)Arm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
United States333568
08

Study locations

1 site
  • Western Regional Medical Center/Cancer Treatment Center of America
    Goodyear, Arizona 85338, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Mar 2018, 34 months.

Results were first posted in Sep 2019, 1 year 6 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 19, 2015
StartActual
May 2015
Primary completionActual
Mar 2018
CompletionActual
Jun 2018
Results first posted
Sep 12, 2019
Last update
Sep 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02448303
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
May 19, 2015
Start date
May 2015
Primary completion
Mar 2018
Completion
Jun 2018
Results posted
Sep 12, 2019
Last update
Sep 12, 2019

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion